Navigation Links
Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference
Date:8/11/2011

WALTHAM, Mass., Aug. 11, 2011 /PRNewswire/ -- Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that CEO Lewis H. Bender will present at the Wedbush Securities Life Sciences Management Access Conference at the Le Parker Meridien Hotel, 119 West 56th Street in New York City. The presentation is scheduled for Wednesday, Aug. 17 at 3:35 p.m. (EDT) in the Lorica Room, located on the second floor.  

Interleukin's management team will be available for one-on-one meetings with investors participating in the Wedbush Securities Life Sciences Management Access Conference.

The presentation will be webcast live at http://www.wsw.com/webcast/wedbush17/iliu/ where it will also be archived for 90 days. The webcast link will also be available through Interleukin's website at http://www.ilgenetics.com.

About Interleukin Genetics, Inc. Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA).  For more information, please visit http://www.ilgenetics.com.Contacts:Media:

Investors:Jon Siegal / Kirsten Fallon

Eliot LurierSchwartz Communications

Interleukin Genetics, Inc.781-684-0770

781-398-0700interleukin@schwartzcomm.com

elurier@ilgenetics.com
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
2. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
3. Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results
4. Interleukin Genetics, Inc. to Present at Biotech Showcase 2011
5. Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex
6. Interleukin Genetics to Present at Upcoming Biotech Industry Meetings
7. Interleukin Genetics to Present at the 12th Annual BIO CEO Conference
8. Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market
9. Interleukin Genetics Reports Second Quarter 2009 Financial Results
10. Interleukin Genetics Announces Conference Call To Discuss Second Quarter 2009 Results
11. Interleukin Genetics to Present at the 2009 BIO Business Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... HOUSTON , Feb. 9, 2016 /PRNewswire/ ... virus-driven immunotherapies for cancer, announced that its ... the European Commission as an orphan medicinal ... the deadliest form of glioma, strikes approximately ... and EU. http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... BOSTON and LONDON , February ... see leading bio tech replace paper and ... The web-based electronic laboratory notebook (ELN) will be rolled out ... replace paper-based research and development (R&D) and protect valuable IP. ... time and follow a specific researcher or experiment as part ...
(Date:2/9/2016)... , Feb. 9, 2016 BERG, ... data-driven, biological research approach, has announced the appointment ... Officer and Chief Operating Officer. Haddock brings to ... finance, including 12 years in senior financial functions ... experience in business organizational management. ...
(Date:2/8/2016)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... technology companies in the TSX Venture 50 TM . ... the TSX Venture Exchange, in each of five major industry ... & life sciences, diversified industries and technology – based on ... investment, market cap growth, trading volume and analyst coverage. All ...
Breaking Biology Technology:
(Date:1/25/2016)... Software, the world-leading supplier of image data management solutions ... data management solution OMERO Plus for the newly established ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... analysis measures the characteristics and behavior of cells, tissues ... as health and disease, the presence or absence of ...
(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
(Date:1/13/2016)... DUBLIN , January 13, 2016 ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the ... & Identification Market - Estimation & ...
Breaking Biology News(10 mins):